Device-detected atrial fibrillation in a large remote-monitored cohort: implications for anticoagulation and need for new pathways of service delivery
ConclusionsDespite being intensively managed via RM software system incorporating cues for anticoagulation, a substantial proportion of patients with increased stroke risk remained unanticoagulated after a device-detected AF episode of significant duration. These data highlight the need for improved clinical response pathways and an integrated care approach to RM.Trial registrationAustralian New Zealand Clinical Trial Registry: ACTRN12620001232921.Graphical Abstract
Source: Journal of Interventional Cardiac Electrophysiology - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Cardiac Resynchronization Therapy | Cardiology | Clinical Trials | Heart | New Zealand Health | Stroke